Navigation Links
Watson Names G. Frederick Wilkinson Executive Vice President, Global Brands
Date:9/21/2009

MORRISTOWN, N.J., Sept. 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals, announced today that G. Frederick Wilkinson has joined the Company as Executive Vice President, Global Brands. In this newly expanded position Mr. Wilkinson will be responsible for all aspects of the Company's global brand pharmaceutical business, including brand product development, global sales and marketing and coordinating brand product business development activities. In addition, Mr. Wilkinson will oversee Watson's biologic development efforts. Mr. Wilkinson will report directly to Paul Bisaro, President and Chief Executive Officer.

"Fred returns to Watson with an extraordinary record of accomplishments having built a successful brand products business at Duramed Pharmaceuticals, the brand business of Barr Pharmaceuticals, particularly in the area of women's healthcare," said Paul Bisaro, Watson CEO. "We will look to Fred to further strengthen our US brand business, which includes a strong product portfolio supported by the recent launches of RAPAFLO(R) and Gelnique(R)."

"Fred's global experience will also be invaluable as we seek to maximize opportunities for our brand portfolio in new markets that will result from the successful acquisition of Arrow Group, which is expected to close this fall," Bisaro added. "Finally, Fred's experience in biologics, including expansion of Barr's biopharmaceutical production capabilities, development of a pipeline of early stage projects, and his work to shepherd Barr's initial biologics vaccine product through the FDA clinical development process, will enable him to effectively guide our efforts in becoming a leader in the generic biologics area."

Most recently, Mr. Wilkinson served as President and Chief Operating Officer of Duramed Pharmaceuticals, Inc., the proprietary products subsidiary of Barr Pharmaceuticals, Inc. He joined Duramed in 2006 and had responsibility for the Company's successful expansion of Duramed's female healthcare product franchise and pipeline, and for managing Barr's biologics initiatives. Prior to joining Duramed Pharmaceuticals, Mr. Wilkinson served as President and Chief Executive Officer of Columbia Laboratories since 2001. From 1996 to 2001, Mr. Wilkinson was Senior Vice President and Chief Operating Officer of Watson Pharmaceuticals. Prior to joining Watson, he spent sixteen years at Sandoz Pharmaceutical Corporation in numerous senior managerial positions of increasing responsibility.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Women's Health and Nephrology (Medical).

For press releases and other company information, visit the Watson Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Quarterly Report on Form 10-Q for the period ended June 30, 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. Watson Names Mark Durand Chief Financial Officer
6. Watson and Novartis Settle Lawsuit Over Exelon(R) Patent Litigation
7. Barr Subsidiary Sues Watson and Sandoz for SEASONALE(R) Patent Infringement
8. Watson Confirms Patent Litigation With Barr Related to Seasonale(R)
9. Watson Receives FDA Approval for Generic DuoNeb(R)
10. Watson to Distribute Alendronate Tablets
11. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... New Jersey (PRWEB) , ... February 11, 2016 , ... ... to a free CEU seminar titled, “Stroke Management: Time to Act, Time to Heal” ... Housing Community in Whippany, N.J. The presenter is Vishal Chedda, president of ANSA ...
(Date:2/11/2016)... ... February 11, 2016 , ... The president released a ... Health System but would shift more of the cost burden to military beneficiaries. ... laid out in the defense budget as including limited quantifiable benefit fixes mixed with ...
(Date:2/11/2016)... ... February 11, 2016 , ... In a new ... plastic surgeon , Dr. Rod J. Rohrich, and colleagues, examine and underscore the ... recommendations for rhinoplasty surgeons when addressing this vital area. , The upper lateral ...
(Date:2/11/2016)... ... February 11, 2016 , ... PharmMD CEO ... Garrett will focus on contract negotiations, corporate strategy and healthcare data law. Additional ... best practices in data breaches for the Part D Star Rating improvement and ...
(Date:2/11/2016)... ... 11, 2016 , ... Talix today announced that Clive Fields, ... presenting at the 2016 HIMSS Annual Conference & Exhibition, taking place February 29 ... “ Coding for Care: Using Data Analytics for Risk Adjustment ,” Dr. Fields ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... 11, 2016  AbbVie, a global biopharmaceutical company, ... designed to provide financial support for exceptional students ... higher education goals. Fifteen scholars will be selected ... year. The AbbVie Rheumatology Scholarship is currently accepting ... president, corporate social responsibility, brand and communications, AbbVie. ...
(Date:2/11/2016)... F ast access to ... at the point of need   ... and services, has launched a ClinicalKey mobile app that enables ... Elsevier designed the mobile app to allow users to select access to ... Android and iOS formats for mobile phone and tablet. ...
Breaking Medicine Technology: